Toward the end of each year, I make stem cell & regenerative medicine predictions for the coming year. It’s a fun tradition here on The Niche that goes way back. The stem cell field has changed dramatically as reflected in each year’s predictions. Here’s a list of past predictions with my grades of how they […]
2023 stem cell & regenerative medicine predictions Read More »
It’s that time of year again when I grade my previous year’s predictions for the stem cell & regenerative medicine space. Overall, I did better than a typical year. I give the 2022 predictions an A- overall. This exercise can be kind of fun but also humbling. For example, I tend to be too optimistic
Grading my 2022 regenerative medicine predictions Read More »
When I’m asked about the most promising areas of stem cell clinical research, cell therapy for type I diabetes is near the top including work by a biotech called ViaCyte. Other firms are in the mix too, boosting the overall odds of success in the coming decade. It’s really that promising even though there are
ViaCyte purchase puts Vertex in driver’s seat on stem cells for diabetes Read More »
Another busy week including on the grant writing treadmill or should I say Mobius strip, but I’m always on the lookout for new reading and this week a lot popped up on regeneration. Also, a paper on healing and scarring. I regularly write about stem cell journals. For a long time, it seems like Cell Stem
Stem cell reads: regeneration, 8C, MYC, CRISPR babies Read More »
The paper of the week reports using base-editing, a kind of gene-editing, to reverse mutations associated with rapid aging syndromes, generally called progeria, but there are a lot of other interesting pubs to recommend for reading this week. I go over it all in this post. Gene-editing to fight premature aging syndromes In vivo base
Weekly reads & paper of the week: gene-editing vs. aging Read More »
Drugs that restore the shape of the errant protein behind cystic fibrosis (CF) have, over the past eight years, helped the majority of patients, who have certain mutations. Gene-corrected stem cells might offer a “mutation agnostic” option to CF. CF results from a glitch in a glycoprotein with the unwieldy name “cystic fibrosis transmembrane conductance
Can Gene-Edited Stem Cells Treat Cystic Fibrosis? Read More »
Another week and more great papers and interesting news in the regenerative medicine sphere including COVID-19 updates, stem cells for vision, and more. Rebuilding Corneas With Stem Cells Stem cell-based regenerative medicine arguably has shown the most promise for vision loss. A PR from Massachusetts Eye and Ear says: Doctors rebuild damaged corneas using patients’
Recommended regenerative medicine reads: COVID-19 updates, Cornea Fix, Pubs Read More »
It was fascinating to read a new JAMA piece by the FDA on unproven stem cell clinics and other regenerative medicine firms. Many of these guys are profiteering off of buzz about exciting, but mostly unproven technologies. While the JAMA opinion piece reiterates the agency’s commitment to evidence-based regenerative medicine, it also makes some other
Striking FDA Hahn & Marks JAMA pub on regenerative clinics Read More »
Despite the COVID-19 pandemic there are still some research things we can do including data analysis as well as reading new papers and media articles on science, including regenerative medicine. If the weather’s good and you have wi-fi (or you print articles still on paper) you can even do this out in the fresh air
Recommended regenerative medicine reads plus COVID-19 stem cell hype Read More »
The Washington Post broke the story this morning that Google has a new biomedical ad policy that may really shake things up for stem cell clinics. The search giant announced the new policy on its blog that will restrict advertisements for unproven stem cell clinics, cellular and gene therapies. This is great news. Google new
Google to block unproven stem cell clinic & gene therapy ads Read More »